Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein

Introduction Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain (FGA) gene, and it is the most common cause of hereditary renal amyloidosis in the UK. Patients typically present with kidney impairment and progress to end-stage renal disease over a median time of 4.6 years. Methods Six patients presented with proteinuria, hypertension, and/or lower limb edema and underwent detailed clinical and laboratory investigations. Results A novel FGA gene mutation was identified in each case: 2 frameshift mutations F521Sfs*27 and G519Efs*30 and 4 single base substitutions G555F, E526K, E524K, R554H. In 5 subjects, extensive amyloid deposits were found solely within the glomeruli, which stained specifically with antibodies to fibrinogen A alpha chain, and in one of these cases, we found coexistent fibrinogen A alpha chain amyloidosis and anti-glomerular basement membrane antibody disease. One patient was diagnosed with light-chain amyloidosis after a bone marrow examination revealed a small clonal plasma cell population, and laser microdissection of the amyloid deposits followed by liquid chromatography and tandem mass spectrometry identified kappa light chain as the fibril protein. Discussion We report 6 novel mutations in the FGA gene: 5 were associated with renal fibrinogen A alpha chain amyloidosis and 1 was found to be incidental to light-chain amyloid deposits discovered in a patient with a plasma cell dyscrasia. Clinical awareness and suspicion of hereditary amyloidosis corroborated by genetic analysis and adequate typing using combined immunohistochemistry and laser microdissection and mass spectrometry is valuable to avoid misdiagnosis, especially when a family history of amyloidosis is absent.

[1]  D. Booth,et al.  Hereditary renal amyloidosis associated with variant lysozyme in a large English family. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  D. Booth,et al.  Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. , 2002, The New England journal of medicine.

[3]  M. Skinner,et al.  New USA Family has Apolipoprotein AI (ARG26) Variant , 1991 .

[4]  J. Kere,et al.  Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene , 1990, FEBS letters.

[5]  J. Liepnieks,et al.  Renal amyloidosis with a frame shift mutation in fibrinogen aalpha-chain gene producing a novel amyloid protein. , 1997, Blood.

[6]  D. Booth,et al.  Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene. , 1996, The Journal of clinical investigation.

[7]  Michael T. Zimmermann,et al.  Novel Type of Renal Amyloidosis Derived from Apolipoprotein-CII. , 2017, Journal of the American Society of Nephrology : JASN.

[8]  J. Liepnieks,et al.  Hereditary renal amyloidosis with a novel variant fibrinogen. , 1994, The Journal of clinical investigation.

[9]  P. Hawkins,et al.  Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  P. Talmud,et al.  D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile , 2016, Nature Communications.

[11]  P. Hawkins,et al.  Amyloid Typing: Experience from a Large Referral Centre , 2012 .

[12]  C. Zeng,et al.  Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. , 2009, Journal of the American Society of Nephrology : JASN.

[13]  D. Booth,et al.  A new apolipoprotein Al variant, Trp50Arg, causes hereditary amyloidosis. , 1995, QJM : monthly journal of the Association of Physicians.

[14]  J. Liepnieks,et al.  A frame shift mutation in the fibrinogen A alpha chain gene in a kindred with renal amyloidosis. , 1996, Blood.

[15]  P. Talmud,et al.  Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia. , 1991, Atherosclerosis.

[16]  D. Booth,et al.  Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family. , 2000, QJM : monthly journal of the Association of Physicians.

[17]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[18]  P. Hawkins,et al.  Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. , 2011, The American journal of pathology.

[19]  E. Arbustini,et al.  The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide. , 1999, The American journal of pathology.

[20]  D. Ostler,et al.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. , 2000, The American journal of pathology.

[21]  D. Booth,et al.  Hereditary nephropathic systemic amyloidosis caused by a novel variant apolipoprotein A-I. , 1998, Kidney international.

[22]  P. Hawkins,et al.  Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Arbustini,et al.  Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. , 2004, Gastroenterology.

[24]  J. Liepnieks,et al.  Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1. , 1999, The American journal of pathology.

[25]  M. Gertz,et al.  Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  J. Ghiso,et al.  Mutation in gelsolin gene in Finnish hereditary amyloidosis , 1990, The Journal of experimental medicine.

[27]  C. Hofmeister,et al.  Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[28]  J. Liepnieks,et al.  Hereditary renal amyloidosis associated with a mutant fibrinogen α–chain , 1993, Nature Genetics.

[29]  J. Liepnieks,et al.  A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. , 1999, Biochemical and biophysical research communications.

[30]  P. Hawkins,et al.  Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. , 2010, Blood.

[31]  D. Booth,et al.  Human lysozyme gene mutations cause hereditary systemic amyloidosis , 1993, Nature.

[32]  H. R. Bergen,et al.  Immunoglobulin derived depositions in the nervous system: novel mass spectrometry application for protein characterization in formalin-fixed tissues , 2008, Laboratory Investigation.

[33]  J. Liepnieks,et al.  A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. , 2001, Genomics.

[34]  J. Ghiso,et al.  Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type. , 1990, The Biochemical journal.